Axcan is a privately-held leading specialty pharmaceutical company focused on gastroenterology. We market a wide range of products to treat gastrointestinal diseases and disorders, such as Inflammatory Bowel Disease, cholestatic liver diseases, Irritable Bowel Syndrome and pancreatic enzyme insufficiency.
Within the framework of its commitment to gastroenterology, Axcan is driven by its dedication to constantly innovate to provide improved therapies and meet patients’ needs.
On February 11, 2011 Axcan completed the acquisition of Eurand N.V., a global specialty pharmaceutical company with operating units in the United States and Europe.
We anticipate that combining our strengths will result in a global specialty pharmaceutical company with complementary GI capabilities, a diversified and strengthened product and technology portfolio, broader development pipeline, expanded manufacturing footprint and enhanced R&D capabilities. Bringing together our world-class talent, brands and technologies will enhance our ability to meet the needs of the patients and caregivers we serve. For more information, please see our press release.
To learn more about Eurand, visit www.eurand.com.